Health Technology · Pharmaceuticals: Major · NSE: AAREYDRUGS · data 2026-10-09
Aarey Drugs & Pharmaceuticals Ltd.
Health check: Average (4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹104.08
Market cap
₹290 cr
P/E
71
P/B
—
ROE
2.7%
ROCE
6.0%
Debt / equity
0.33
Dividend yield
0.00%
1-year return
26.9%
52-week high
₹110
52-week low
₹50.31
Operating margin
0.9%
Growth
| Revenue (last 12 months) | ₹415 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | 4.1% |
| Profit growth, 3 years (yearly) | 1.7% |
Chart patterns
- Double bottom — breakout (key level ₹87.5)
- Ascending triangle — forming (key level ₹103.99)
Similar companies
Medicamen Biotech Limited (MEDICAMEQ) · Jenburkt Pharmaceuticals Ltd (JENBURPH) · Ambalal Sarabhai Enterprises Limited (AMBALALSA) · Brooks Laboratories Limited (BROOKS) · Nectar Lifesciences Ltd. (NECLIFE)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AAREYDRUGS in NSE Scanner →